Cognite Recognized as a Leader in Industrial Data Management Solutions
Independent Research Firm positions Cognite Data Fusion® as a market-leading DataOps and AI platform for enterprise-scale, complex industrial data management projects
Cognite, the global leader in AI for industry, today announced it has been named a Leader in the Verdantix Green Quadrant: Industrial Data Management Solutions 2025 report for providing a market-leading DataOps and AI platform for enterprise-scale, complex Industrial Data Management (IDM) projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114915194/en/
Verdantix Green Quadrant: Industrial Data Management Solutions 2025 (Graphic: Business Wire)
The report recognizes Cognite's platform, Cognite Data Fusion®, for its deeply configurable unstructured and structured industrial data orchestration, fast-paced product development, and world-class offering for complex asset-heavy industrial data and AI projects.
Cognite received a perfect score for its ‘data modeling’ capabilities, the foundational element of Cognite Data Fusion® that enables Cognite customers to adapt to emerging trends and stay ahead in a rapidly evolving technological climate. Additionally, Cognite received perfect scores across 'indirect industrial data acquisition,' 'platform development environment,' and 'platform APIs,' and the highest score for 'unstructured data utilization’ of all data platforms reviewed.
Verdantix also highlighted Cognite Atlas AI™ as an example of innovation in making industrial AI work for practical applications. With its focus on real-world usability, Cognite Atlas AI™ was called out for its ability to streamline agent-driven data retrieval and interpretation, supported by an industrial benchmarking report that helps organizations select the most suitable LLMs for their specific use cases.
“Industrial data management solutions play a critical role in enabling organizations to effectively integrate and leverage their data, particularly as AI becomes increasingly central to industrial operations,” said Joe Lamming, Senior Analyst, Industrial Transformation at Verdantix. “Cognite’s market-leading data modeling capabilities contextualize diverse data types, from structured time series to unstructured documents. We see such capabilities as vital for bridging the gap between raw data and actionable insights and automation. Solutions like those offered by Cognite show how industrial knowledge graphs can ground AI applications in domain-specific, cross-referenced truth, enabling organizations to build useful information systems in complex OT, IT, and ET environments.”
"Data modeling is the cornerstone of Cognite's approach to tackling complex industrial challenges," said Geir Engdahl, Chief Product Officer at Cognite. "Our advanced techniques, including our industrial agent workbench Cognite Atlas AI™, bridge the gap between raw data and actionable insights, making information accessible and meaningful to both humans and AI systems. As generative AI reshapes the industrial landscape, our commitment to robust and flexible data modeling ensures we empower customers with the right foundation for innovative AI-powered solutions tailored to their operational realities."
Cognite Data Fusion® serves as the cornerstone of Cosmo Energy's Digitalization (DX) aspirations," said Noriko Rzonca, Ph.D., Chief Digital Officer Cosmo Energy Holdings. “Generative AI-driven data modeling with Cognite empowers our operations to be safer and more optimized. We are thrilled to see them receive this well-deserved recognition as a leader in Industrial Management Solutions."
Read the full report here: Cognite recognized as a leader in Industrial Data Management solutions
Request a demo of Cognite Data Fusion® and Cognite Atlas AI™ here: cognite.com/request-demo
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
About Verdantix
Verdantix is the essential thought-leader for world-enhancing innovation. We support change-makers with our proprietary data, unique expertise and executive networks. Our impactful analysis is delivered via a digital platform, consulting engagements and in-person events to thousands of decision-makers in more than 100 countries. From offices in London, New York and Boston, the Verdantix research team applies the principles of rigour, accuracy and curiosity to help our globally distributed clients solve their most complex challenges. verdantix.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114915194/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom